AN2 Therapeutics Inc (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of its upsized initial public offering of 4,600,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares of common stock are being offered by AN2 Therapeutics. The gross proceeds to AN2 Therapeutics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AN2 Therapeutics, are expected to be $69.0 million. In addition, AN2 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 690,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The shares are expected to begin trading on the Nasdaq Global Select Market on March 25, 2022 under the symbol ANTX. The offering is expected to close on March 29, 2022, subject to the satisfaction of customary closing conditions.
Cowen, SVB Leerink, and Evercore ISI are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as a lead manager for the offering.
Source: AN2 Therapeutics, Inc.